WINTON GROUP Ltd Grows Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

WINTON GROUP Ltd lifted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 12.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 137,216 shares of the biopharmaceutical company’s stock after purchasing an additional 14,797 shares during the quarter. WINTON GROUP Ltd owned about 0.13% of Catalyst Pharmaceuticals worth $789,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Teacher Retirement System of Texas purchased a new stake in Catalyst Pharmaceuticals during the first quarter worth about $51,000. E Fund Management Co. Ltd. purchased a new stake in shares of Catalyst Pharmaceuticals during the 1st quarter worth approximately $84,000. Brookstone Capital Management acquired a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter worth approximately $91,000. Lazard Asset Management LLC purchased a new position in Catalyst Pharmaceuticals in the 1st quarter valued at approximately $99,000. Finally, One Wealth Advisors LLC acquired a new position in Catalyst Pharmaceuticals during the first quarter worth $101,000. Institutional investors and hedge funds own 73.27% of the company’s stock.

In related news, Director Philip H. Coelho sold 9,498 shares of the stock in a transaction on Wednesday, August 25th. The stock was sold at an average price of $5.56, for a total value of $52,808.88. Following the completion of the sale, the director now directly owns 233,427 shares in the company, valued at approximately $1,297,854.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Steve Miller sold 80,000 shares of the company’s stock in a transaction dated Wednesday, August 25th. The stock was sold at an average price of $5.56, for a total value of $444,800.00. Following the completion of the sale, the chief operating officer now directly owns 821,724 shares of the company’s stock, valued at approximately $4,568,785.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 326,276 shares of company stock worth $1,827,885. 11.70% of the stock is currently owned by insiders.

Shares of NASDAQ CPRX opened at $5.05 on Friday. The firm’s 50 day moving average price is $5.53 and its 200 day moving average price is $5.14. The firm has a market cap of $520.04 million, a P/E ratio of 7.21 and a beta of 1.34. Catalyst Pharmaceuticals, Inc. has a 1 year low of $2.88 and a 1 year high of $6.24.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Sunday, August 8th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.10 by $0.01. The company had revenue of $36.37 million during the quarter, compared to analysts’ expectations of $31.25 million. Catalyst Pharmaceuticals had a return on equity of 28.22% and a net margin of 58.80%. Analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 0.39 EPS for the current fiscal year.

Several research firms have recently issued reports on CPRX. Piper Sandler lifted their price target on Catalyst Pharmaceuticals from $5.50 to $6.50 and gave the stock an “overweight” rating in a research note on Tuesday, August 10th. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a research report on Thursday, August 12th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Catalyst Pharmaceuticals in a research report on Tuesday. Finally, Roth Capital restated a “buy” rating on shares of Catalyst Pharmaceuticals in a research report on Sunday, August 15th. Four analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $7.95.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms.

Featured Article: Dividend Yield

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX).

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.